Post by Alira Health

For health technologies that fall under JCA, patient involvement can no longer be viewed as a purely national activity. Companies should plan when and how patient input will be used across EU joint work, while still recognizing that part of the HTA process will remain in the hands of Member States. Learn more below and start reading here: https://lnkd.in/dKb_hga3 This latest article outlines: 🔹Where patient involvement fits within JSC and JCA 🔹What will continue to happen at a national level 🔹How health technology developers can prepare for a more coordinated approach to patient engagement under EU HTA Looking for an expert team to support your HTAR readiness? We provide end-to-end support aligned with the EU HTA process, from early development through JCA and national market access. Contact us at [email protected] to learn more.